{"id":469478,"date":"2024-01-04T15:38:48","date_gmt":"2024-01-04T20:38:48","guid":{"rendered":"https:\/\/platohealth.ai\/c4x-discovery-advancing-drug-discovery-with-nrf2-activator-program\/"},"modified":"2024-01-04T15:39:01","modified_gmt":"2024-01-04T20:39:01","slug":"c4x-discovery-advancing-drug-discovery-with-nrf2-activator-program","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/c4x-discovery-advancing-drug-discovery-with-nrf2-activator-program\/","title":{"rendered":"C4X Discovery: Advancing Drug Discovery with NRF2 Activator Program","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<header>\n<\/header>\n<footer class=\"post-meta\">\n<\/footer>\n<section>\n<p>C4X Discovery Holdings plc (AIM: C4XD), a drug discovery company, recently announced a significant milestone in its partnership with AstraZeneca. The company received an $11 million payment, a testament to the preclinical advancements in its NRF2 Activator program, reflecting a promising start to 2024 for C4XD.<\/p>\n<p>The collaboration between C4X Discovery and AstraZeneca, initiated in November 2022, revolves around the development of C4XD&#8217;s NRF2 Activator program. As part of the exclusive worldwide license agreement, C4XD initially received a $2 million upfront payment and stands to gain up to $400 million more, contingent on the achievement of various preclinical, clinical, and commercial milestones. Additionally, C4XD is eligible for tiered mid-single digit royalties on future sales of products derived from this collaboration.<\/p>\n<p>AstraZeneca&#8217;s development of the NRF2 Activator program underlines the program&#8217;s potential in treating inflammatory and respiratory diseases. The focus is on creating an oral therapy, primarily targeting chronic respiratory diseases. NRF2, known for its challenging nature in drug discovery, plays a critical role in regulating antioxidant response in cells, making it a key target for treating diseases with underlying inflammatory processes.<\/p>\n<\/section>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.amplifipr.com\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platodata-network\">PlatoData.Network Vertical Generative Ai. Empower Yourself. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platodata.network\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoaistream\">PlatoAiStream. Web3 Intelligence. Knowledge Amplified. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoesg\">PlatoESG. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/carbon\/\">Carbon,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/cleantech\/\">CleanTech,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/energy\/\">Energy,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/environment\/\">Environment,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/solar\/\">Solar,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/waste-management\/\">Waste Management.<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platohealth\">PlatoHealth. Biotech and Clinical Trials Intelligence. <a href=\"https:\/\/platohealth.ai\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.biopharmatrend.com\/post\/728-c4x-discovery-advancing-drug-discovery-with-nrf2-activator-program\/\">https:\/\/www.biopharmatrend.com\/post\/728-c4x-discovery-advancing-drug-discovery-with-nrf2-activator-program\/<\/a><\/li>\n<\/ul>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>C4X Discovery Holdings plc (AIM: C4XD), a drug discovery company, recently announced a significant milestone in its partnership with AstraZeneca. The company received an $11 million payment, a testament to the preclinical advancements in its NRF2 Activator program, reflecting a promising start to 2024 for C4XD. The collaboration between C4X Discovery and AstraZeneca, initiated in [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":469481,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/469478"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=469478"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/469478\/revisions"}],"predecessor-version":[{"id":469480,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/469478\/revisions\/469480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/469481"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=469478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=469478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=469478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}